These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 37683329

  • 1. Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy.
    Weinhofer I, Rommer P, Gleiss A, Ponleitner M, Zierfuss B, Waidhofer-Söllner P, Fourcade S, Grabmeier-Pfistershammer K, Reinert MC, Göpfert J, Heine A, Yska HAF, Casasnovas C, Cantarín V, Bergner CG, Mallack E, Forss-Petter S, Aubourg P, Bley A, Engelen M, Eichler F, Lund TC, Pujol A, Köhler W, Kühl JS, Berger J.
    EBioMedicine; 2023 Oct; 96():104781. PubMed ID: 37683329
    [Abstract] [Full Text] [Related]

  • 2. Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy.
    Weinhofer I, Rommer P, Zierfuss B, Altmann P, Foiani M, Heslegrave A, Zetterberg H, Gleiss A, Musolino PL, Gong Y, Forss-Petter S, Berger T, Eichler F, Aubourg P, Köhler W, Berger J.
    Nat Commun; 2021 Mar 22; 12(1):1816. PubMed ID: 33753741
    [Abstract] [Full Text] [Related]

  • 3. Antioxidant Capacity and Superoxide Dismutase Activity in Adrenoleukodystrophy.
    Turk BR, Theisen BE, Nemeth CL, Marx JS, Shi X, Rosen M, Jones RO, Moser AB, Watkins PA, Raymond GV, Tiffany C, Fatemi A.
    JAMA Neurol; 2017 May 01; 74(5):519-524. PubMed ID: 28288261
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of Neurofilament Light Chain as a Biomarker of Neurodegeneration in X-Linked Childhood Cerebral Adrenoleukodystrophy.
    Wang H, Davison MD, Kramer ML, Qiu W, Gladysheva T, Chiang RMS, Kayatekin C, Nascene DR, Taghizadeh LA, King CJ, Nolan EE, Gupta AO, Orchard PJ, Lund TC.
    Cells; 2022 Mar 07; 11(5):. PubMed ID: 35269535
    [Abstract] [Full Text] [Related]

  • 5. Elevated cerebral spinal fluid cytokine levels in boys with cerebral adrenoleukodystrophy correlates with MRI severity.
    Lund TC, Stadem PS, Panoskaltsis-Mortari A, Raymond G, Miller WP, Tolar J, Orchard PJ.
    PLoS One; 2012 Mar 07; 7(2):e32218. PubMed ID: 22359672
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. MicroRNA Profiling Identifies miR-196a as Differentially Expressed in Childhood Adrenoleukodystrophy and Adult Adrenomyeloneuropathy.
    Shah N, Singh I.
    Mol Neurobiol; 2017 Mar 07; 54(2):1392-1403. PubMed ID: 26843114
    [Abstract] [Full Text] [Related]

  • 8. Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy.
    van Ballegoij WJC, van de Stadt SIW, Huffnagel IC, Kemp S, Willemse EAJ, Teunissen CE, Engelen M.
    Ann Clin Transl Neurol; 2020 Nov 07; 7(11):2127-2136. PubMed ID: 33047897
    [Abstract] [Full Text] [Related]

  • 9. Neurofilament light chain levels in cerebrospinal fluid as a sensitive biomarker for cerebral adrenoleukodystrophy.
    Kakumoto T, Matsukawa T, Ishiura H, Mori H, Tsuji S, Toda T.
    Ann Clin Transl Neurol; 2023 Jul 07; 10(7):1230-1238. PubMed ID: 37259474
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Glycoprotein nonmetastatic melanoma protein B (GNMPB) as a novel biomarker for cerebral adrenoleukodystrophy.
    Taghizadeh LA, King CJ, Nascene DR, Gupta AO, Orchard PJ, Higgins L, Markowski TW, Nolan EE, Furcich JW, Lund TC.
    Sci Rep; 2022 May 14; 12(1):7985. PubMed ID: 35568699
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Adrenal insufficiency as part of X-linked adrenoleukodystrophy].
    Enikeeva SR, Chugunov IS, Kareva MA, Kurkina MV, Zakharova EY, Michailova SV, Bezlepkina OB, Peterkova VA, Mokrysheva NG.
    Probl Endokrinol (Mosk); 2023 Dec 05; 70(3):83-92. PubMed ID: 39069776
    [Abstract] [Full Text] [Related]

  • 14. Cerebrospinal fluid matrix metalloproteinases are elevated in cerebral adrenoleukodystrophy and correlate with MRI severity and neurologic dysfunction.
    Thibert KA, Raymond GV, Nascene DR, Miller WP, Tolar J, Orchard PJ, Lund TC.
    PLoS One; 2012 Dec 05; 7(11):e50430. PubMed ID: 23185624
    [Abstract] [Full Text] [Related]

  • 15. Inflammatory profile in X-linked adrenoleukodystrophy patients: Understanding disease progression.
    Marchetti DP, Donida B, Jacques CE, Deon M, Hauschild TC, Koehler-Santos P, de Moura Coelho D, Coitinho AS, Jardim LB, Vargas CR.
    J Cell Biochem; 2018 Jan 05; 119(1):1223-1233. PubMed ID: 28722826
    [Abstract] [Full Text] [Related]

  • 16. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
    Rasing I, Voigt S, Koemans EA, de Kort AM, van Harten TW, van Etten ES, van Zwet EW, Stoops E, Francois C, Kuiperij HB, Klijn CJM, Schreuder FHBM, van der Weerd L, van Osch MJP, van Walderveen MAA, Verbeek MM, Terwindt GM, Wermer MJH.
    Alzheimers Res Ther; 2024 Apr 23; 16(1):86. PubMed ID: 38654326
    [Abstract] [Full Text] [Related]

  • 17. Functional Characterization of IPSC-Derived Brain Cells as a Model for X-Linked Adrenoleukodystrophy.
    Baarine M, Khan M, Singh A, Singh I.
    PLoS One; 2015 Apr 23; 10(11):e0143238. PubMed ID: 26581106
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.